Company intelligence / Profile preview

Lanzhou Biotechnique Development

Lanzhou, Gansu, China

Ownership: Private
Development stage: Other

Overview

Lanzhou Biotechnique Development Co. Ltd. manufactures Botulinum toxin type A for strabismus and aesthetic indications (approved in China) and is leading Phase 3 trials for hyaluronic acid dermal fillers in partnership with Croma-Pharma/CNBG. The company is active in biopharmaceutical manufacturing, medical aesthetics, and provides high-quality therapeutic/Biotech products for diseases of the immune and nervous system, as well as aesthetic medicine.

Therapeutic areas: ImmunologyNeurologyDermatologyOphthalmology
Modalities: ToxinBiologicHyaluronic acid dermal fillerDeviceSmall molecule
Industry: Biotech

Drug pipeline

2 assets

modified sodium hyaluronate

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Croma-PharmaCNBG

Beyond the preview

Go deeper on Lanzhou Biotechnique Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lanzhou Biotechnique Development.

Explore the full profile